CROI 2015 Program and Abstracts

Abstract Listing

Poster Abstracts

Prevalence of and factors independently associated with diabetes mellitus among HIV-infected adults receiving medical care in the United States, Medical Monitoring Project, 2009- 2010

*P <0.05; †In addition to the variables presented in the table, the prevalence ratio is adjusted for education level, poverty, and geometric mean CD4 cell count during the 12 months prior to interview; weighted diabetes prevalence includes diagnosed and undiagnosed individuals; BMI = body mass index; CI = confidence interval Conclusions: In the United States, one in seven HIV-infected adults has diagnosed or undiagnosed DM. Compared to the general population aged 20-44 years, same-aged HIV-infected adults are over twice as likely to have DM. Although obesity is a major risk factor for DM among HIV-infected adults, our data suggest that DMmay be present at an earlier age in the context of HIV-infection and in the absence of traditional risk factors. Healthcare providers should implement recommended screening for DM to promote early interventions including lifestyle modifications for individuals with and at higher risk for DM. 790 Functional Vitamin D Deficiency With Initiation of Tenofovir-Based ART? Evelyn Hsieh 1 ; Liana Fraenkel 1 ;Weibo Xia 2 ;Yang Han 2 ; MichaelTYin 3 ; Karl Insogna 4 ;Ting Zhu 2 ;Taisheng Li 2 1 Yale University School of Medicine, New Haven, CT, US; 2 Peking Union Medical College Hospital, Beijing, China; 3 Columbia University Medical Center, New York, NY, US; 4 Yale University School of Medicine, New Haven, CT, US Background: Antiretroviral regimens containing tenofovir disoproxil fumarate (TDF) have been associated with decreases in bone mineral density (BMD), and elevations in bone turnover markers (BTM) and intact parathyroid hormone (iPTH) in patients with HIV. Prior cross-sectional studies suggested that a functional vitamin D deficiency may in part explain these changes. To explore this hypothesis further, we measured change in plasma vitamin D binding protein (VDBP) levels from baseline to 48 weeks among a cohort of patients treated with TDF/lamivudine(3TC)/efavirenz(EFV) in the context of other serologic markers of vitamin D and bone metabolism. Methods: We performed a secondary analysis using plasma samples collected at 0, 24, and 48 weeks after initiation of TDF/3TC/EFV from 140 adult participants enrolled in a multi-center randomized trial. Women over 45 years were excluded to avoid confounding due to menopausal status. Data regarding socio-demographic characteristics, BMI, CD4 + counts, and HIV viral load were obtained as part of the parent study. Laboratory analyses included plasma VDBP, iPTH, total 25-hydroxyvitamin D (25OHD), the bone resorption marker collagen type 1 cross-linked C-telopeptide (CTX), and the bone formation marker total procollagen type 1 N-terminal propeptide (P1NP). Differences between time points were compared using the paired t-test. Results: Our sample included 110 men and 30 women with a mean age of 33 ± 9.6 yrs. Mean BMI remained stable from 0 to 48 wks (21.7 ± 3.0 v. 22.0 ± 3.2 kg/m 2 , p=0.20), however mean CD4 + count increased significantly (279.5 ± 117.1 v. 424.6 ± 176.9 cells/mm 3 , p<0.001) and median viral load decreased from 53767 (IQR: 19802 to 136493) to 0 (IQR:0 to 10) copies/mL. Significant increases were observed in VDBP levels from 0 to 24 wks followed by smaller increases from 24 to 48 wks (see Table 1). Similar increases were detected in iPTH levels, however 25OHD levels remained relatively stable. BTM levels increased significantly from 0 to 24 wks followed by a slight decline (CTX) or stabilization (P1NP), however remained significantly higher compared with baseline at 48 wks.

Poster Abstracts

482

CROI 2015